Patents by Inventor Daniele Sblattero

Daniele Sblattero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to ?2-glycoprotein I and therapeutic uses thereof
    Patent number: 9777057
    Abstract: Human recombinant antibodies or fragments thereof having specificity for the ?2-glycoprotein I (?2GPI), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (APS).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: October 3, 2017
    Assignee: ONCONOX APS
    Inventors: Francesco Tedesco, Pier Luigi Meroni, Daniele Sblattero
  • ANTIBODIES TO ß2-GLYCOPROTEIN I AND THERAPEUTIC USES THEREOF
    Publication number: 20160152696
    Abstract: Human recombinant antibodies or fragments thereof having specificity for the ?2-glycoprotein I (?2GPI), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (APS).
    Type: Application
    Filed: July 7, 2014
    Publication date: June 2, 2016
    Applicant: ONCONOX APS
    Inventors: Francesco TEDESCO, Pier Luigi MORONI, Daniele SBLATTERO
  • Recombinant antibodies against CD55 and CD59 and uses thereof
    Patent number: 8034902
    Abstract: The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: October 11, 2011
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Roberto Marzari, Daniele Sblattero, Francesco Tedesco
  • Recombinant antibodies against cd55 and cd59 and uses thereof
    Publication number: 20090053225
    Abstract: The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20.
    Type: Application
    Filed: May 1, 2006
    Publication date: February 26, 2009
    Inventors: Roberto Marzari, Daniele Sblattero, Francesco Tedesco